Heron Therapeutics (HRTX) Enterprise Value (2010 - 2026)

Heron Therapeutics has reported Enterprise Value for 17 years, with the latest figure at -$30.0 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value rose 15.85% year-over-year to -$30.0 million; the trailing twelve-month figure through Mar 2026 stood at -$30.0 million (up 15.85% YoY), and the FY2025 full-year result was -$29.6 million, up 16.38% from the prior year.
• Enterprise Value for Q1 2026 stood at -$30.0 million, down from -$29.6 million in the prior quarter.
• The five-year high for Enterprise Value was -$29.3 million in Q3 2025, with the low at -$121.7 million in Q3 2022.
• Historically, Enterprise Value has averaged -$52.4 million across 5 years, with a median of -$40.6 million in 2025.
• Annual changes were most pronounced in 2022 — Enterprise Value soared 84.78% — and 2024, when it tumbled 102.58%.
• Heron Therapeutics' Enterprise Value stood at -$71.0 million in 2022, then gained by 19.66% to -$57.0 million in 2023, then soared by 37.96% to -$35.4 million in 2024, then rose by 16.38% to -$29.6 million in 2025, then decreased by 1.29% to -$30.0 million in 2026.
• The last three Enterprise Value figures came in at -$30.0 million (Q1 2026), -$29.6 million (Q4 2025), and -$29.3 million (Q3 2025), per Business Quant data.